Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Fractionation of Testosterone Cypionate in Transgender Men with Erythrocytosis
NCT05487794Completed
- Sponsor
- Universidade de São Paulo
- Start
- Sep 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of testosterone cypionate in Gender incongruence (GI) (2 arms), sponsored by Universidade de São Paulo. Primary endpoint: Rate of Erythrocytosis (Hematocrit Level) at 3 months. Started Sep 2022; status: completed.
02
Drugs
testosterone cypionate
03
Conditions
Gender incongruence (GI)
Beyond the preview
Go deeper on NCT05487794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05487794.